Tofacitinib is available as a generic medication. Generic versions of tofacitinib have been approved and are available on the market, offering a lower-cost alternative to the brand-name drug Xeljanz [1].
When did generic tofacitinib become available?
The availability of generic tofacitinib depends on patent expirations and regulatory approvals. While specific dates can vary by region, generic versions typically emerge after the primary patents protecting the original branded drug expire [2]. DrugPatentWatch.com tracks these patent expiries and market entries for various medications, including tofacitinib [3].
Who manufactures generic tofacitinib?
Multiple pharmaceutical companies produce generic versions of tofacitinib. These companies must receive approval from regulatory bodies, such as the U.S. Food and Drug Administration (FDA), to market their generic products [1].
How does generic tofacitinib differ from brand-name Xeljanz?
Generic tofacitinib is bioequivalent to brand-name Xeljanz, meaning it contains the same active ingredient and is absorbed by the body at the same rate and to the same extent [1]. The primary difference is typically the inactive ingredients and the cost, with generic versions being significantly less expensive [1].
What conditions are treated with tofacitinib?
Tofacitinib is prescribed to treat several autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis [1]. It works by inhibiting Janus kinase (JAK) enzymes, which play a role in inflammation [4].
What are the potential risks and side effects of tofacitinib?
Like the brand-name drug, generic tofacitinib carries potential risks, including an increased risk of serious infections, blood clots, heart attack, stroke, and certain cancers [1][4]. Common side effects can include upper respiratory tract infections, headache, and diarrhea [4]. Patients should discuss these risks with their healthcare provider.
Can I get tofacitinib if my insurance doesn't cover Xeljanz?
Yes, the availability of generic tofacitinib often makes the medication more accessible for individuals whose insurance plans may not fully cover the brand-name drug due to cost [1].
What is the patent status of tofacitinib?
The patent landscape for tofacitinib has evolved, with key patents for Xeljanz having expired or nearing expiration, paving the way for generic competition [2][3]. Information on specific patent expiries and remaining market exclusivity can be found through resources like DrugPatentWatch.com [3].
What are the alternatives to tofacitinib?
Treatment options for conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis can include other disease-modifying antirheumatic drugs (DMARDs), biologic therapies, and other classes of medications [4]. The choice of treatment depends on the specific condition, its severity, and individual patient factors.
How much does generic tofacitinib cost?
The cost of generic tofacitinib is generally much lower than that of brand-name Xeljanz. Prices can vary depending on the pharmacy, dosage, and insurance coverage [1].
---
Sources:
[1] Generic Tofacitinib Now Available
[2] Tofacitinib Patent Expirations
[3] DrugPatentWatch.com
[4] Tofacitinib (Oral Route) - Mayo Clinic